Title: Nutritional composition for treating inflammatory bowel diseases
United States Patent: 6,214,373Inventors: Snowden; Robert B. (Churchville, PA)
Assignee: Snowden-Sutton Associates, Inc. (Churchville, PA)Appl. No.: 414666
Filed: October 7, 1999
A nutritional composition and method useful for treatment of inflammatory bowel diseases is disclosed, the composition comprising selected vitamins and mineral salts for oral administration to a subject having an inflammatory bowel disease. The composition comprises an excess of vitamin D and vitamin B12, contains vitamin C and iron in quantities promoting good absorption, contains water miscible forms of the fat soluble vitamins, and no phosphate or carbonate salts. Preferably, the iron is present as ferrous fumarate. And, preferably the composition is essentially free of magnesium.
DETAILED DESCRIPTION OF THE INVENTION
I have developed a new nutritional composition, useful for
treating subjects having an inflammatory bowel disease such as Crohn's
disease or ulcerative colitis. The new nutritional composition combines in
a mixture, selected vitamins in proportions that make the composition
especially well suited for treating such subjects. The composition also
includes selected minerals in proportions that are also especially well
suited for treating these subjects. The minerals are preferably present in
the composition as salts that will neither give rise to, nor promote the
formation of gas in the subject's digestive system.
TABLE 1 Vitamin A 1,500 to 5,000 IU Vitamin D 200 to 600 IU Vitamin E 15 to 100 IU Vitamin K 15 to 60 mcg Vitamin C 30 to 150 mg Vitamin B1 1 to 6 mg Vitamin B2 1 to 6 mg Vitamin B6 1 to 6 mg Vitamin B12 150 to 1,000 mcg Folic Acid 0.2 to 0.5 mg Niacin 5 to 20 mg Biotin 0.1 to 0.2 mg Pantothenic acid 2 to 8 mg Iron 6 to 20 mg Calcium 50 to 200 mg Zinc 5 to 15 mg Selenium 20 to 50 mcg Copper 0.5 to 1.5 mg Iodine 60 to 80 mcg Manganese 0.5 to 1.5 mgThe individual vitamins may be included in the composition in more than one form and still be encompassed by the teachings of the invention. For example, vitamin A may be included as retinyl acetate, beta-carotene, retinoic acid, or retinal. Vitamin E may be included as dl-alpha tocopherol acetate, succinate, or phosphate. Vitamin C may be included as ascorbic acid, ascorbate salts, or vitamin C esters. Vitamin B1 may be included as thiamine mononitrate, hydrochloride, monophosphate chloride, or pyrophosphate chloride. Vitamin B6 may be included as pyridoxine hydrochloride or pyridoxal phosphate.
A preferred composition for use according to the teachings of the invention is the embodiment shown in Table 2.
TABLE 2 Vitamin A (retinyl acetate) 2,500 IU Vitamin D (cholecalciferol) 400 IU Vitamin E (dl-alpha tocopherol acetate) 75 IU Vitamin K (phytonadione) 40 mcg Vitamin C (ascorbic acid) 100 mg Vitamin B1 (thiamine mononitrate) 5 mg Vitamin B2 (riboflavin) 5 mg Vitamin B6 (pyridoxine hydrochloride) 5 mg Vitamin B12 (cyanocobalamin) 500 mcg Folic Acid 0.2 mg Niacin (niacinamide) 10 mg Biotin 0.15 mg Pantothenic acid 5 mg Iron 15 mg Calcium 100 mg Zinc 11.25 mg Selenium 35 mcg Copper 1.0 mg Iodine 75 mcg Manganese 1.0 mgIn a preferred embodiment, the inventive composition comprises mineral salts selected from the group consisting of phosphates, sulfates, and fumarates. It is especially preferred that the inventive composition is essentially free of any carbonate. That is, the composition preferably has no significant amount of carbonate present. This is to avoid the possibility of gas generation within the gastrointestinal tract of a subject receiving the composition.
It is also preferred that the inventive composition is essentially free of magnesium, so as to avoid its cathartic effect. Preferably, the inventive composition is also essentially free of lactose, other sugars, colorants, artificial sweeteners and flavorings. These are also to be avoided to prevent the effects of these substances on the gastrointestinal tract of a subject having IBD or celiac disease.
A method of treating a subject who has an inflammatory bowel disease or celiac disease is also contemplated as being associated with the present invention. The new method may be carried out by providing a composition, as disclosed above, and administering the composition orally to the subject. This method may be carried out by administering the composition in either a solid dosage form, or in a liquid dosage form.
The present invention also includes a method of making a medicament that comprises the new composition disclosed here. This method involves mixing the vitamins and minerals in the amounts disclosed here, where the medicament is intended for use in treating ulcerative colitis, Crohn's disease, or celiac disease. The medicament being made can be in either a solid dosage form, or a liquid dosage form.
The present invention is not to be limited in scope by the embodiments disclosed herein in the Tables, which are intended as single illustrations of one aspect of the invention, and any which are functionally equivalent are within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein, will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims. All patents and any publications mentioned herein are hereby incorporated by reference.
Claim 1 of 18 Claims